Charles Schwab Investment Management Inc. boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price objective raised by JPMorgan Chase & Co. from $39.00 to $41.00 in a research note released on Thursday morning,Benzinga reports.

JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

SMid Biotech Analyst Rama provides a quick recap of Revuforj Physician Survey results on a conference call to be held on March 20 at 10 am ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reported its first quarter with product revenue, generating $7.7 million from Revv Forge in just five weeks post-launch. The FDA approved Revv Forge ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company developing an innovative pipeline ...